QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
NASDAQ:CTSO

Cytosorbents Stock Forecast, Price & News

$5.84
+0.01 (+0.17 %)
(As of 10/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.80
$5.89
50-Day Range
$5.85
$9.71
52-Week Range
$5.73
$11.68
Volume
165,327 shs
Average Volume
290,987 shs
Market Capitalization
$253.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.3
30 days | 90 days | 365 days | Advanced Chart
Receive CTSO News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytosorbents and its competitors with MarketBeat's FREE daily newsletter.


Cytosorbents logo

About Cytosorbents

CytoSorbents Corp. engages in the critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio include CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CTSO
Employees
195
Year Founded
N/A

Sales & Book Value

Annual Sales
$41.01 million
Book Value
$1.83 per share

Profitability

Net Income
$-7.84 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$253.27 million
Next Earnings Date
11/4/2021 (Confirmed)
Fiscal Year End
N/A
Optionable
Optionable

MarketRank

Overall MarketRank

1.83 out of 5 stars

Medical Sector

764th out of 1,371 stocks

Surgical & Medical Instruments Industry

79th out of 125 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Cytosorbents (NASDAQ:CTSO) Frequently Asked Questions

Is Cytosorbents a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cytosorbents stock.
View analyst ratings for Cytosorbents
or view top-rated stocks.

What stocks does MarketBeat like better than Cytosorbents?

Wall Street analysts have given Cytosorbents a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cytosorbents wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Cytosorbents?

Cytosorbents saw a decrease in short interest in the month of October. As of October 15th, there was short interest totaling 1,520,000 shares, a decrease of 20.0% from the September 30th total of 1,900,000 shares. Based on an average daily volume of 284,800 shares, the short-interest ratio is presently 5.3 days. Currently, 4.0% of the company's stock are short sold.
View Cytosorbents' Short Interest
.

When is Cytosorbents' next earnings date?

Cytosorbents is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Cytosorbents
.

How can I listen to Cytosorbents' earnings call?

Cytosorbents will be holding an earnings conference call on Thursday, November 4th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Cytosorbents' earnings last quarter?

Cytosorbents Co. (NASDAQ:CTSO) issued its quarterly earnings results on Tuesday, August, 3rd. The medical research company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by $0.08. The medical research company had revenue of $12.02 million for the quarter, compared to the consensus estimate of $12.29 million. Cytosorbents had a negative trailing twelve-month return on equity of 13.33% and a negative net margin of 22.97%.
View Cytosorbents' earnings history
.

How has Cytosorbents' stock price been impacted by Coronavirus (COVID-19)?

Cytosorbents' stock was trading at $4.77 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CTSO shares have increased by 22.4% and is now trading at $5.84.
View which stocks have been most impacted by COVID-19
.

What guidance has Cytosorbents issued on next quarter's earnings?

Cytosorbents updated its third quarter 2021 earnings guidance on Tuesday, October, 26th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $9.70 million-$9.70 million, compared to the consensus revenue estimate of $11.96 million.

What price target have analysts set for CTSO?

4 analysts have issued 12-month price targets for Cytosorbents' shares. Their forecasts range from $10.00 to $17.00. On average, they anticipate Cytosorbents' stock price to reach $13.33 in the next twelve months. This suggests a possible upside of 128.3% from the stock's current price.
View analysts' price targets for Cytosorbents
or view top-rated stocks among Wall Street analysts.

Who are Cytosorbents' key executives?

Cytosorbents' management team includes the following people:
  • Phillip P. Chan, Chief Executive Officer & Director
  • Vincent J. Capponi, President & Chief Operating Officer
  • Kathleen P. Bloch, Chief Financial Officer & Secretary
  • Steven Sisk, Director-Clinical Operations
  • Efthymios N. Deliargyris, Chief Medical Officer

What is Phillip Chan's approval rating as Cytosorbents' CEO?

2 employees have rated Cytosorbents CEO Phillip Chan on Glassdoor.com. Phillip Chan has an approval rating of 26% among Cytosorbents' employees. This puts Phillip Chan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cytosorbents own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytosorbents investors own include NanoViricides (NNVC), Rekor Systems (REKR), Advanced Micro Devices (AMD), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), AbbVie (ABBV), Inovio Pharmaceuticals (INO), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

What is Cytosorbents' stock symbol?

Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO."

How do I buy shares of Cytosorbents?

Shares of CTSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cytosorbents' stock price today?

One share of CTSO stock can currently be purchased for approximately $5.84.

How much money does Cytosorbents make?

Cytosorbents has a market capitalization of $253.27 million and generates $41.01 million in revenue each year. The medical research company earns $-7.84 million in net income (profit) each year or ($0.20) on an earnings per share basis.

How many employees does Cytosorbents have?

Cytosorbents employs 195 workers across the globe.

What is Cytosorbents' official website?

The official website for Cytosorbents is www.cytosorbents.com.

Where are Cytosorbents' headquarters?

Cytosorbents is headquartered at 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852.

How can I contact Cytosorbents?

Cytosorbents' mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The medical research company can be reached via phone at (732) 329-8885 or via email at [email protected].


This page was last updated on 10/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.